Roles of atrial natriuretic peptide and its therapeutic use

Journal of Cardiology

Volumn 56, Issue 3, 2010, Pages 262-270

  Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Arial natriuretic peptide; Heart failure; Heart failure treatment; Prognosis; Renal function

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIURETIC AGENT; GLYCERYL TRINITRATE; NESIRITIDE; NITRATE;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; ANGIOGENESIS; CARDIOPULMONARY BYPASS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; HEART CATHETERIZATION; HEART DISEASE; HEART FAILURE; HEART SURGERY; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY DISEASES; MICE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ATRIAL NATRIURETIC FACTOR; VENTRICULAR REMODELING;

EID: 78049432152     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.08.001     Document Type: Review

References (50)

1. de Bold A.J., Flynn T.G. Cardionatrin I-a novel heart peptide with potent diuretic and natriuretic properties. Life Sci 1983, 33:297-302.
2. Kangawa K., Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 1984, 118:131-139.
3. Nakao K., Ogawa Y., Suga S., Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertens 1992, 10:907-912.
4. Nakao K., Ogawa Y., Suga S., Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: natriuretic peptide receptors. J Hypertens 1992, 10:1111-1114.
5. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
6. Dontas I.D., Xanthos T., Dontas I., Lelovas P., Papadimitriou L. Impact of nesiritide on renal function and mortality in patients suffering from heart failure. Cardiovasc Drugs Ther 2009, 23:221-233.
7. Mentzer R.M., Oz M.C., Sladen R.N., Graeve A.H., Hebeler R.F., Luber J.M., Smedira N.G. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol 2007, 49:716-726. NAPA Investigators.
8. Kisch B. Electron microscopy of the atrium of the heart. Exp Med Surg 1956, 14:99-112.
9. de Bold A.J. Heart atria granularity effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979, 161:508-511.
10. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
11. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990, 168:863-870.
12. Saito Y., Nakao K., Itoh H., Yamada T., Mukoyama M., Arai H., Hosoda K., Shirakami G., Suga S., Minamino N., Kangawa K., Matsuo H., Imura H. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989, 158:360-368.
13. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., Shirakami G., Jougasaki M., Obata K., Yasue H. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87:1402-1412.
14. Ogawa Y., Nakao K., Mukoyama M., Shirakami G., Saito Y., Arai H., Suga S., Jougasaki M., Itoh H., Hosoda K., Yamada T., Kambayashi Y., Inouye K., Imura H. Rat brain natriuretic peptide-Tissue distribution and molecular form. Endocrinology 1990, 126:2225-2227.
15. Hofmann F., Bernhard D., Lukowski R., Weinmeister P. cGMP regulated protein kinases (cGK): a textbook of cGMP: generators, effectors and therapeutic implications 2009, Springer, Verlag, Berlin, Heidelberg, Germany, pp. 137-162.
16. Tang K.M., Wang G.R., Lu P., Karas R.H., Aronovitz M., Heximer S.P., Kaltenbronn K.M., Blumer K.J., Siderovski D.P., Zhu Y., Mendelsohn M.E. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003, 9:1506-1512.
17. Sabrane K., Kruse M.N., Fabritz L., Zetsche B., Mitko D., Skryabin B.V., Zwiener M., Baba H.A., Yanagisawa M., Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 2005, 115:1666-1674.
18. Abassi Z.A., Winaver J., Skorecki K.L. Control of extracellular fluid volume and the pathophysiology of edema formation: a textbook of disturbances in control of body fluid volume and composition. Brenner & Rector's The Kidney 1999, vol. 1:777-855. The Kidney, Philadelphia, Saunders, USA. 7th ed.
19. John S.W., Krege J.H., Oliver P.M., Hagaman J.R., Hodgin J.B., Pang S.C., Flynn T.G., Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995, 267:679-681.
20. Lopez M.J., Wong S.K., Kishimoto I., Dubois S., Mach V., Friesen J., Garbers D.L., Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995, 378:65-68.
21. Li Y., Saito Y., Kuwahara K., Rong X., Kishimoto I., Harada M., Adachi Y., Nakanishi M., Kinoshita H., Horiuchi M., Murray M., Nakao K. Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart. Circulation 2002, 106:1722-1728.
22. Holtwick R., van Eickels M., Skryabin B.V., Baba H.A., Bubikat A., Begrow F., Schneider M.D., Garbers D.L., Kuhn M. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003, 111:1399-1407.
23. Tokudome T., Kishimoto I., Horio T., Arai Y., Schwenke D.O., Hino J., Okano I., Kawano Y., Kohno M., Miyazato M., Nakao K., Kangawa K. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008, 117:2329-2339.
24. Zhang Q., Saito Y., Naya N., Imagawa K., Somekawa S., Kawata H., Takeda Y., Uemura S., Kishimoto I., Nakao K. The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A. Hypertens Res 2008, 31:1251-1256.
25. Holtwick R., Gotthardt M., Skryabin B., Steinmetz M., Potthast R., Zetsche B., Hammer R.E., Herz J., Kuhn M. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci USA 2002, 99:7142-7147.
26. Sabrane K., Kruse M.N., Gazinski A., Kuhn M. Chronic endothelium-dependent regulation of arterial blood pressure by atrial natriuretic peptide: role of nitric oxide and endothelin-1. Endocrinology 2009, 150:2382-2387.
27. Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., Mukoyama M., Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993, 88:82-91.
28. Mizuno Y., Yasue H., Oshima S., Yoshimura M., Ogawa H., Morita E., Saito T., Yamashita S., Noda K., Sumida H., Motoyama T., Soejima H., Nakao K. Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction. J Card Fail 1997, 3:287-293.
29. Nakanishi M., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., Kawakami R., Nakagawa Y., Tanimoto K., Yasuno S., Usami S., Li Y., Adachi Y., Fukamizu A., Garbers D.L., et al. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 2005, 46:441-447.
30. Izumi T., Saito Y., Kishimoto I., Harada M., Kuwahara K., Hamanaka I., Takahashi N., Kawakami R., Li Y., Takemura G., Fujiwara H., Garbers D.L., Mochizuki S., Nakao K. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 2001, 108:203-213.
31. Kawakami R., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., Nakagawa Y., Nakanishi M., Tanimoto K., Usami S., Yasuno S., Kinoshita H., Chusho H., Tamura N., Ogawa Y., et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 2004, 110:3306-3312.
32. Kasahara M., Mukoyama M., Sugawara A., Makino H., Suganami T., Ogawa Y., Nakagawa M., Yahata K., Goto M., Ishibashi R., Tamura N., Tanaka I., Nakao K. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 2000, 11:1691-1701.
33. Suganami T., Mukoyama M., Sugawara A., Mori K., Nagae T., Kasahara M., Yahata K., Makino H., Fujinaga Y., Ogawa Y., Tanaka I., Nakao K. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol 2001, 12:2652-2663.
34. Makino H., Mukoyama M., Mori K., Suganami T., Kasahara M., Yahata K., Nagae T., Yokoi H., Sawai K., Ogawa Y., Suga S., Yoshimasa Y., Sugawara A., Tanaka I., Nakao K. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 2006, 49:2514-2524.
35. Tokudome T., Kishimoto I., Yamahara K., Osaki T., Minamino N., Horio T., Sawai K., Kawano Y., Miyazato M., Sata M., Kohno M., Nakao K., Kangawa K. Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-A, a receptor for atrial and brain natriuretic peptides. Arterioscler Thromb Vasc Biol 2009, 29:1516-1521.
36. Kuhn M., Völker K., Schwarz K., Carbajo-Lozoya J., Flögel U., Jacoby C., Stypmann J., van Eickels M., Gambaryan S., Hartmann M., Werner M., Wieland T., Schrader J., Baba H.A. The natriuretic peptide/guanylyl cyclase-a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest 2009, 119:2019-2030.
37. Yamahara K., Itoh H., Chun T.H., Ogawa Y., Yamashita J., Sawada N., Fukunaga Y., Sone M., Yurugi-Kobayashi T., Miyashita K., Tsujimoto H., Kook H., Feil R., Garbers D.L., Hofmann F., et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci USA 2003, 100:3404-3409.
38. Saito Y., Nakao K., Nishimura K., Sugawara A., Okumura K., Obata K., Sonoda R., Ban T., Yasue H., Imura H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 1987, 76:115-124.
39. Cody R.J., Atlas S.A., Laragh J.H., Kubo S.H., Covit A.B., Ryman K.S., Shaknovich A., Pondolfino K., Clark M., Camargo M.J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986, 78:1362-1374.
40. Crozier I.G., Nicholls M.G., Ikram H., Espiner E.A., Gomez H.J., Warner N.J. Haemodynamic effects of atrial peptide infusion in heart failure. Lancet 1986, 2:1242-1245.
41. Suwa M., Seino Y., Nomachi Y., Matsuki S., Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 2005, 69:283-290.
42. Nomura F., Kurobe N., Mori Y., Hikita A., Kawai M., Suwa M., Okutani Y. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J 2008, 72:1777-1786.
43. Hata N., Seino Y., Tsutamoto T., Hiramitsu S., Kaneko N., Yoshikawa T., Yokoyama H., Tanaka K., Mizuno K., Nejima J., Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J 2008, 72:1787-1793.
44. Ishikawa C., Tsutamoto T., Wada A., Fujii M., Ohno K., Sakai H., Yamamoto T., Horie M. Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure. J Cardiovasc Pharmacol 2005, 46:513-518.
45. Shono M., Yoshimura M., Nakayama M., Yamamuro M., Abe K., Suzuki S., Mizuno Y., Sugiyama S., Saito Y., Nakao K., Yasue H., Ogawa H. Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J 2007, 71:1040-1046.
46. Hayashi M., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Tsutsui T., Horie H., Ohnishi M., Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001, 37:1820-1826.
47. Kitakaze M., Asakura M., Kim J., Shintani Y., Asanuma H., Hamasaki T., Seguchi O., Myoishi M., Minamino T., Ohara T., Nagai Y., Nanto S., Watanabe K., Fukuzawa S., Hirayama A., et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007, 370:1483-1493.
48. Sezai A., Shiono M., Orime Y., Hata H., Hata M., Negishi N., Sezai Y. Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 2000, 69:732-738.
49. Morikawa S., Sone T., Tsuboi H., Mukawa H., Morishima I., Uesugi M., Morita Y., Numaguchi Y., Okumura K., Murohara T. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 2009, 53:1040-1046.
50. Kimura K., Yamaguchi Y., Horii M., Kawata H., Yamamoto H., Uemura S., Saito Y. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 2007, 63:699-702.